AEON Biopharma, Inc. (NASDAQ:AEON – Get Free Report) fell 5.9% during mid-day trading on Friday . The company traded as low as $0.71 and last traded at $0.77. 102,100 shares traded hands during trading, a decline of 85% from the average session volume of 678,235 shares. The stock had previously closed at $0.82.
Wall Street Analyst Weigh In
Separately, HC Wainwright cut their price target on shares of AEON Biopharma from $6.00 to $5.00 and set a “buy” rating on the stock in a research note on Wednesday, August 14th.
Check Out Our Latest Report on AEON Biopharma
AEON Biopharma Price Performance
AEON Biopharma (NASDAQ:AEON – Get Free Report) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.03. Analysts predict that AEON Biopharma, Inc. will post -0.77 earnings per share for the current year.
Hedge Funds Weigh In On AEON Biopharma
An institutional investor recently raised its position in AEON Biopharma stock. Vanguard Group Inc. increased its holdings in shares of AEON Biopharma, Inc. (NASDAQ:AEON – Free Report) by 261.8% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 758,992 shares of the company’s stock after purchasing an additional 549,207 shares during the quarter. Vanguard Group Inc. owned approximately 2.01% of AEON Biopharma worth $8,804,000 as of its most recent SEC filing. Institutional investors own 22.78% of the company’s stock.
AEON Biopharma Company Profile
AEON Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder.
Further Reading
- Five stocks we like better than AEON Biopharma
- ETF Screener: Uses and Step-by-Step Guide
- Does GTA VI Make Take-Two Interactive Stock an Irresistible Buy?
- P/E Ratio Calculation: How to Assess Stocks
- Why HPE’s Dip Is a Prime Opportunity for Blue-Chip AI Investors
- What is a support level?
- Why Analysts See Big Upside for Occidental Petroleum Despite Lows
Receive News & Ratings for AEON Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEON Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
